223 related articles for article (PubMed ID: 19124250)
21. Antitumor efficacy and molecular mechanism of TLK58747, a novel DNA-alkylating prodrug.
Xu H; Wang Z; Donaldson JC; Yao H; Zhou S; Kelson AB; Ma W; Weber KT; Laborde E; Cheng M; Sambucetti L; Keck JG
Anticancer Res; 2009 Oct; 29(10):3845-55. PubMed ID: 19846918
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and antitumor evaluation of novel benzo[d]pyrrolo[2,1-b]thiazole derivatives.
Chaniyara R; Tala S; Chen CW; Lee PC; Kakadiya R; Dong H; Marvania B; Chen CH; Chou TC; Lee TC; Shah A; Su TL
Eur J Med Chem; 2012 Jul; 53():28-40. PubMed ID: 22507893
[TBL] [Abstract][Full Text] [Related]
23. Structure-activity relationships for 4-nitrobenzyl carbamates of 5-aminobenz[e]indoline minor groove alkylating agents as prodrugs for GDEPT in conjunction with E. coli nitroreductase.
Hay MP; Atwell GJ; Wilson WR; Pullen SM; Denny WA
J Med Chem; 2003 Jun; 46(12):2456-66. PubMed ID: 12773049
[TBL] [Abstract][Full Text] [Related]
24. Structure-activity study with bioreductive benzoquinone alkylating agents: effects on DT-diaphorase-mediated DNA crosslink and strand break formation in relation to mechanisms of cytotoxicity.
Fourie J; Guziec F; Guziec L; Monterrosa C; Fiterman DJ; Begleiter A
Cancer Chemother Pharmacol; 2004 Mar; 53(3):191-203. PubMed ID: 14614574
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of fluorenhymustine as a rationally designed novel anticancer agent.
Samanta S; Pain A; Ghosh M; Dutta S; Sanyal U
Exp Oncol; 2005 Dec; 27(4):279-85. PubMed ID: 16404347
[TBL] [Abstract][Full Text] [Related]
26. Polymeric tubulysin-peptide nanoparticles with potent antitumor activity.
Schluep T; Gunawan P; Ma L; Jensen GS; Duringer J; Hinton S; Richter W; Hwang J
Clin Cancer Res; 2009 Jan; 15(1):181-9. PubMed ID: 19118045
[TBL] [Abstract][Full Text] [Related]
27. Chloroacetaldehyde: mode of antitumor action of the ifosfamide metabolite.
Brüggemann SK; Radike K; Braasch K; Hinrichs J; Kisro J; Hagenah W; Peters SO; Wagner T
Cancer Chemother Pharmacol; 2006 Feb; 57(3):349-56. PubMed ID: 16133533
[TBL] [Abstract][Full Text] [Related]
28. CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy.
Bao R; Lai CJ; Qu H; Wang D; Yin L; Zifcak B; Atoyan R; Wang J; Samson M; Forrester J; DellaRocca S; Xu GX; Tao X; Zhai HX; Cai X; Qian C
Clin Cancer Res; 2009 Jun; 15(12):4046-57. PubMed ID: 19509149
[TBL] [Abstract][Full Text] [Related]
29. Design, synthesis, and in vitro evaluation of dipeptide-based antibody minor groove binder conjugates.
Jeffrey SC; Torgov MY; Andreyka JB; Boddington L; Cerveny CG; Denny WA; Gordon KA; Gustin D; Haugen J; Kline T; Nguyen MT; Senter PD
J Med Chem; 2005 Mar; 48(5):1344-58. PubMed ID: 15743178
[TBL] [Abstract][Full Text] [Related]
30. Unsymmetrical DNA cross-linking agents: combination of the CBI and PBD pharmacophores.
Tercel M; Stribbling SM; Sheppard H; Siim BG; Wu K; Pullen SM; Botting KJ; Wilson WR; Denny WA
J Med Chem; 2003 May; 46(11):2132-51. PubMed ID: 12747786
[TBL] [Abstract][Full Text] [Related]
31. Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics.
Hinman LM; Hamann PR; Wallace R; Menendez AT; Durr FE; Upeslacis J
Cancer Res; 1993 Jul; 53(14):3336-42. PubMed ID: 8324745
[TBL] [Abstract][Full Text] [Related]
32. Novel acid labile COL1 trityl-linked difluoronucleoside immunoconjugates: synthesis, characterization, and biological activity.
Patel VF; Hardin JN; Mastro JM; Law KL; Zimmermann JL; Ehlhardt WJ; Woodland JM; Starling JJ
Bioconjug Chem; 1996; 7(4):497-510. PubMed ID: 8853464
[TBL] [Abstract][Full Text] [Related]
33. Anti-tumor efficacy of Cloretazine (VNP40101M) alone and in combination with fludarabine in murine tumor and human xenograft tumor models.
Zheng LM; Li Z; Liu L; Song BL; King I
Cancer Chemother Pharmacol; 2007 Jun; 60(1):45-51. PubMed ID: 17256135
[TBL] [Abstract][Full Text] [Related]
34. Preclinical evaluation of the pharmacodynamic properties of 2,5-diaziridinyl-3-hydroxymethyl-6-methyl-1,4-benzoquinone.
Ward TH; Danson S; McGown AT; Ranson M; Coe NA; Jayson GC; Cummings J; Hargreaves RH; Butler J
Clin Cancer Res; 2005 Apr; 11(7):2695-701. PubMed ID: 15814651
[TBL] [Abstract][Full Text] [Related]
35. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
Chari RV
Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and in vitro cytotoxicity of 9-anilinoacridines bearing N-mustard residue on both anilino and acridine rings.
Chen CH; Lin YW; Zhang X; Chou TC; Tsai TJ; Kapuriya N; Kakadiya R; Su TL
Eur J Med Chem; 2009 Jul; 44(7):3056-9. PubMed ID: 18752869
[TBL] [Abstract][Full Text] [Related]
37. DNA cross-links in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism, and cytotoxicity.
Singleton RS; Guise CP; Ferry DM; Pullen SM; Dorie MJ; Brown JM; Patterson AV; Wilson WR
Cancer Res; 2009 May; 69(9):3884-91. PubMed ID: 19366798
[TBL] [Abstract][Full Text] [Related]
38. Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agents in the MV522 lung tumor model.
Kelner MJ; McMorris TC; Rojas RJ; Estes LA; Suthipinijtham P
Cancer Chemother Pharmacol; 2008 Dec; 63(1):19-26. PubMed ID: 18305940
[TBL] [Abstract][Full Text] [Related]
39. Chemical structure and tumor type specificity of "half-mustard type" phenothiazines.
Motohashi N; Kurihara T; Sakagami H; Szabo D; Csuri K; Molnár J
Anticancer Res; 1999; 19(3A):1859-64. PubMed ID: 10470128
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of naphthalmustine, a nitrogen mustard derivative of naphthalimide as a rationally-designed anticancer agent.
Pain A; Samanta S; Dutta S; Saxena AK; Shanmugavel M; Kampasi H; Qazi GN; Sanyal U
J Exp Clin Cancer Res; 2003 Sep; 22(3):411-8. PubMed ID: 14582700
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
